

CORRECTIONS & AMENDMENTS

CORRIGENDUM

doi:10.1038/nature09476

Treatment frontiers

Kerri Smith

Nature **466** (suppl.), S15–S18 (26 August 2010)

This Outlook article stated that Addex Pharmaceuticals has mGluR5 modulators in phase II trials for anxiety and depression. The company says that its only disclosed mGluR5 inhibitor in development, ADX48621, will soon enter phase II testing for Parkinson's disease levodopa-induced dyskinesia and non-Parkinson's dystonia.